Dr. Reddy's Laboratories Limited (ADR) (NYSE:RDY)
| CAPS Rating |
|
|---|
RDY
VS S&P 500 (SPY)
RDY News and Commentary
- Encouraging Data on Lilly Drug - Analyst Blog – NASDAQ
- Dr. Reddy's Laboratories Should Continue To Gain Market Share In Lucrative Markets – SeekingAlpha
- The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva Pharmaceuticals and Dr. – NASDAQ
- Genpact: To Provide Finance, Accounting Services To Dr Reddy's – SmartMoney
- Generic Launches Continue at Mylan - Analyst Blog – NASDAQ
- RDY Adds to Generic Portfolio - Analyst Blog – NASDAQ
- Bristol-Myers Squibb's Thud Heard Round the World – The Motley Fool
- Dr. Reddy's Launches Plavix' Generic - Analyst Blog – NASDAQ
- UPDATE:FDA Approves Generic Versions Of Blood-Thinning Drug Plavix – SmartMoney
How do you think RDY will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
504
Outperform
29
Underperform
All-Star Players
104
Outperform
6
Underperform
Wall Street
4
Outperform
2
Underperform
RSS Headlines
Fool UK
